Lawsuit alleges Ozempic and Mounjaro describe “severe” gastroparesis

A personal injury law firm sued Novo Nordisk and Eli Lilly, alleging that the manufacturers “underestimated the seriousness of gastrointestinal events caused by Ozempic and Mounjaro,” such as gastroparesis and gastroenteritis.

The plaintiff, Jacqueline Bjorklund, has reportedly been described Ozembic (Simaglutide, Novo Nordisk)a glucagon-like peptide-1 receptor agonist, was used to treat type 2 diabetes for more than a year before it was converted to Monjaro (Terzipatide, Eli Lilly) in July 2023.

Björklund claims her use of both Ozempic and Mounjaro resulted in serious gastrointestinal events, including “severe vomiting, stomach pain, GI burning sensation, and hospitalizations for stomach problems on several occasions including visits to the emergency room,”( f) Loss of teeth due to excessive vomiting, which requires additional medication to relieve excessive vomiting and vomiting of food entirely hours after eating.

Although abdominal pain, constipation, diarrhea, nausea, and vomiting are listed as possible adverse events in the prescribing information for both Ozempic and Mounjaro, the lawsuit asserts that the manufacturers “underestimated the severity of gastrointestinal events caused by Ozempic and Mounjaro, never, for example, warning of risk of gastroparesis or gastroenteritis.”

While Ozempic’s drug label does not mention gastroparesis, Monjaro label It explicitly states that the drug has not been studied in patients with “severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in these patients”. In addition, the suit does not disclose whether the plaintiff was formally diagnosed with either gastroparesis or gastroparesis Inflammation of the stomach and intestines.

The lawsuit alleges that the manufacturers showed “total disregard and reckless indifference to the safety and well-being of the general public” by either failing to warn patients or insufficiently warning them of all potential side effects associated with the use of Ozempic and Mounjaro, as well. as a failure to disclose that these drugs “have not been adequately and/or adequately tested for safety risks”.

Bjorklund’s attorneys are seeking compensatory and punitive damages for their client’s “pain and suffering due to severe and permanent personal injury,” health care costs and medical observation, as well as court and legal fees.

reference: